Feb 1, 2021 | 2021, Past Events
Feb 1, 2021 | 2021, Investors, Press Releases
PRESS RELEASE – 01/02/2021 COMUNICATO STAMPA – 01/02/2021Jan 13, 2021 | 2021, Press Releases, Scientific
NidlegyTMwas found to be well-tolerated and 149 out of the anticipated 214 patients have been safely treated. Data Safety Monitoring Board recommends to continue the study as planned. PRESS RELEASE – 13/01/2021Nov 9, 2020 | 2020, Past Events
Philogen will be attending the PEGS Europe Virtual Conference from November 9 to 12, 2020. Co-founder and Chief Scientific Officer, Prof. Dario Neri will give a Keynote Presentation in the Tumor Microenvironment Session (Immunotherapy Stream) on November 10 with the...Nov 2, 2020 | 2020, Past Events
Philogen will be attending the Next Generation Protein Therapeutics & Bioconjugates Summit from November 2 to 5, 2020. Co-founder and Chief Scientific Officer, Prof. Dario Neri will give a Keynote Lecture with the title: Cancer Therapy Using Antibody-Cytokine...
Recent Comments